VIVUS' (Nasdaq: VVUS ) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its sales are lagging. Because only 20% of patients are able to get the drug covered by insurance, there is currently a 30% abandonment rate of patients who decide they can't afford to keep taking it. The stock did rally a bit at the end of the month when Aetna announced that it would begin covering Qsymia and Arena's (Nasdaq: ARNA ) Belviq in the same space, so investors are optimistic that as insurance coverage widens, sales will improve.
The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including Qsymia, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health care writer on the job, so make sure to secure a copy today by clicking here now.